Oosthuizen Johannes Jacobus 4

What Happened
Johannes Jacobus Oosthuizen, Executive Vice President, Oncology & International at Merck & Co. (MRK), was granted two derivative awards on 2026-05-05 totaling 41,649 restricted stock units (RSUs): 10,605 RSUs and 31,044 RSUs. Each award is reported at $0.00 (typical for equity grants); the awards represent a contingent right to receive Merck common stock when they vest.

Key Details

• Transaction date: 2026-05-05; Form 4 filed 2026-05-07 (appears timely).
• Grants: 10,605 RSUs and 31,044 RSUs; reported price $0.00 because these are awards (derivative).
• Vesting: These RSUs vest and will be distributed as shares in three equal installments on 5/5/2027, 5/5/2028 and 5/5/2029 (footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 clarifies each RSU equals a right to one share; F2 gives the vesting schedule. F3 references option vesting language included in the filing package but the listed transactions are RSU grants.
• Transaction type: Award/grant (A) — not an open-market purchase or sale.

Context
RSU grants are compensation awards and do not indicate an immediate cash purchase or sale; the economic value will be realized if and when RSUs vest and convert to shares (based on Merck’s stock price at that time). For retail investors, awards signal executive compensation decisions but are not a direct bullish/bearish trade like an open-market purchase or sale.